Agency Information Collection Activities: Proposed Collection; Comment Request, 27339-27341 [2019-12340]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 113 / Wednesday, June 12, 2019 / Notices
Executive Boulevard, Rockville, MD 20852
(Virtual Meeting).
Contact Person: Rebecca Steiner Garcia,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6149, MSC 9608,
Bethesda, MD 20892, 301–443–4525,
steinerr@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; R34
Refinement and Testing of Interventions to
Sustain ADHD Treatment Effects.
Date: July 10, 2019.
Time: 12:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852
(Virtual Meeting).
Contact Person: Karen Gavin-Evans, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6153, MSC 9606,
Bethesda, MD 20892, 301–443–2356,
gavinevanskm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: June 7, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–12368 Filed 6–11–19; 8:45 am]
Dated: June 7, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–12369 Filed 6–11–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
Substance Abuse and Mental Health
Services Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency Information Collection
Activities: Proposed Collection;
Comment Request
National Institutes of Health
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
jbell on DSK3GLQ082PROD with NOTICES
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Alcohol Abuse and
Alcoholism, 6700B Rockledge Drive, Room
2114, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Ranga Srinivas, Ph.D.,
Chief Extramural Project Review Branch,
National Institute on Alcohol Abuse and
Alcoholism, National Institutes of Health,
6700 B Rockledge Drive, Room 2114,
Bethesda, MD 20892, (301) 451–2067,
srinivar@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards., National
Institutes of Health, HHS)
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; Mechanistic Studies on
Chronic Alcohol and Sleep R01 Review Panel
RFA–AA–19–006.
Date: July 26, 2019.
Time: 11:00 a.m. to 2:00 p.m.
VerDate Sep<11>2014
17:00 Jun 11, 2019
Jkt 247001
In compliance with section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
1112.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
PO 00000
Frm 00109
Fmt 4703
Sfmt 4703
27339
of automated collection techniques or
other forms of information technology.
Proposed Project: 2020 National Survey
on Drug Use and Health Clinical
Validation Study and Redesign Field
Test (OMB No. 0930–0110)—Revision to
2019 NSDUH Collection
The National Survey on Drug Use and
Health (NSDUH) is a survey of the U.S.
civilian, non-institutionalized
population aged 12 years old or older.
The data are used to determine the
prevalence of use of tobacco products,
alcohol, illicit substances, and illicit use
of prescription drugs. The results are
used by SAMHSA, the Office of
National Drug Control Policy (ONDCP),
federal government agencies, and other
organizations and researchers to
establish policy, direct program
activities, and better allocate resources.
2020 NSDUH Main Study—
NSDUH must be updated periodically
to reflect changing substance use and
mental health issues and to continue
producing current data. For the 2020
NSDUH main study the following
changes from 2019 are planned: (1) The
addition of lifetime and recency
questions about vaping anything and
vaping nicotine or tobacco; the addition
of lifetime and recency questions on
synthetic marijuana and synthetic
stimulants; (2) the addition of questions
in concordance with the Diagnostic and
Statistical Manual of Mental Disorders
(DSM), fifth edition criteria (DSM–5) to
measure the occurrence of marijuana
withdrawal symptoms, occurrence of
prescription tranquilizer misuse
withdrawal symptoms and occurrence
of craving for all substances; (3) minor
revisions to the marijuana marketplace
module; and (4) other minor wording
changes to improve the flow of the
interview, increase respondent
comprehension or to be consistent with
text in other questions.
By including these new questions in
NSDUH, estimates may be generated on
the use of these substances among the
general population and allow SAMHSA
to provide national-level estimates
among adults and adolescents on the
use of vaping, synthetic marijuana, and
synthetic stimulants. In addition,
because NSDUH collects demographic,
socioeconomic, and health information
about each respondent, the inclusion of
these questions would permit a more
detailed understanding of factors
associated with their use.
The new questions on craving for all
substances and withdrawal for
marijuana/cannabis were added to the
2020 NSDUH main study to reflect the
updated DSM–5 diagnostic criteria for
substance use disorders. Questions
E:\FR\FM\12JNN1.SGM
12JNN1
27340
Federal Register / Vol. 84, No. 113 / Wednesday, June 12, 2019 / Notices
measuring withdrawal for tranquilizers
have been added to ensure SUD for
tranquilizers is accurately assessed as
well.
The marijuana marketplace module
(originally dropped in the 2015 redesign
questionnaire) was reinserted in the
NSDUH main study questionnaire
starting in 2018 at the request of ONDCP
but was unchanged from the version
previously used in the 2014 NSDUH.
(This module was not part of the
NSDUH questionnaire from 2015–2017.)
This module consists of a series of
questions that seek to gather data such
as the location, quantity, cost and type
of marijuana being purchased across the
nation. Revisions have been made to
this module for 2020 to reflect the
availability that marijuana can now be
purchased from a retail store or
dispensary.
As with all NSDUH/NHSDA surveys
conducted since 1999, the sample size
of the NSDUH main study for 2020 will
be sufficient to permit prevalence
estimates for each of the fifty states and
the District of Columbia. (Prior to 2002,
the NSDUH was referred to as the
National Household Survey on Drug
Abuse (NHSDA).) The total annual
burden estimate for the NSDUH main
study is shown below in Table 1.
TABLE 1—ANNUALIZED ESTIMATED BURDEN FOR 2020 NSDUH
Number of
respondents
Instrument
Responses
per
respondent
Total number
of responses
Hours per
response
Total burden
hours
Household Screening ...........................................................
Interview ...............................................................................
Screening Verification ..........................................................
Interview Verification ............................................................
143,255
69,007
4,348
10,351
1
1
1
1
143,255
69,007
4,348
10,351
0.083
1.000
0.067
0.067
11,890
69,007
291
694
Total ..............................................................................
143,255
........................
226,961
........................
81,882
Clinical Validation Study—
In addition, a Clinical Validation
Study (CVS) is planned to be embedded
within the first six months of 2020
NSDUH main study data collection to
assess revisions to the substance use
disorders (SUD) module to be consistent
with the DSM–5. The CVS will examine
the validity of this revised NSDUH
assessment of SUD by administering
questions to adults and adolescents who
will then be interviewed by clinical
interviewers (who are blinded to the
NSDUH main study responses) and
classified as having or not having
substance use disorders based on past
year DSM–5 disorders, as assessed by
the Structured Clinical Interview for
DSM–5 (SCID–5).
During CVS data collection from
January through June 2020,
approximately 1,500 NSDUH main
study interview respondents will be
selected for a follow-up clinical
interview at the end of the main study
interview in order to produce a final
sample size of approximately 825 CVS
respondents. These follow-up clinical
interviews will be conducted via
telephone using the SCID–5 within two
to four weeks following the NSDUH
main study interview.
Many of the procedures and protocols
planned for inclusion in this CVS are
based upon those previously employed
as part of the 2018 National Mental
Health Study (approved under OMB No.
0930–0380) and the 2008–2012 NSDUH
Mental Health Surveillance Study
(approved as an add-on to NSDUH
under OMB No. 0930–0110).
Also, to complete training prior to
CVS data collection, each clinical
interviewer candidate hired must
successfully administer the follow-up
clinical interview with a volunteer
respondent. These 70 certification
interviews will be administered in the
same manner as CVS follow-up clinical
interviews.
The total annual burden estimate for
the CVS is shown below in Table 2.
TABLE 2—ANNUALIZED ESTIMATED BURDEN FOR 2020 NSDUH CVS
Number of
respondents
jbell on DSK3GLQ082PROD with NOTICES
Instrument
Responses
per
respondent
Total number
of responses
Hours per
response
Total burden
hours
Follow-Up Clinical Interviews ...............................................
Follow-Up Clinical Certifications ..........................................
826
70
1
1
826
70
0.83
0.83
686
58
Total ..............................................................................
896
........................
896
........................
744
Redesign Field Test—
Also, as part of SAMHSA’s ongoing
effort to ensure NSDUH continues
producing current and accurate data, a
Redesign Field Test (FT) is planned
from August through November 2020 to
assess potential revisions to the NSDUH
main study questionnaire. These
revisions are designed to address
changing policy and research data
needs; in addition, modifications to
associated survey materials and
methods are designed to improve the
VerDate Sep<11>2014
17:00 Jun 11, 2019
Jkt 247001
quality of estimates and the efficiency of
data collection. Planned FT
modifications include changes to
respondent incentives, respondent
materials, the household screening
questionnaire, the interview
questionnaire, and other data collection
methods.
The FT is essential for providing a
thorough examination of these planned
changes prior to their deployment on
the NSDUH main study to determine
potential impact across operational and
PO 00000
Frm 00110
Fmt 4703
Sfmt 4703
substantive domains, including effects
on data quality (as measured by
outcomes such as unit nonresponse,
item nonresponse, and survey
responses), questionnaire timing, data
collection efficiency, and possible
differences in reporting of substance use
or mental health items.
During FT data collection from
August through November 2020,
conducted separately from ongoing 2020
NSDUH main study data collection at
that time, screenings will be completed
E:\FR\FM\12JNN1.SGM
12JNN1
27341
Federal Register / Vol. 84, No. 113 / Wednesday, June 12, 2019 / Notices
with approximately 8,110 Englishspeaking respondents in the contiguous
United States. (Alaska and Hawaii are
excluded from the FT to control study
costs.) From those screenings,
approximately 4,000 respondents, as
representatives of the civilian,
noninstitutional population aged 12
years old or older, are expected to
complete a FT interview using the
revised questionnaire and materials.
For the NSDUH FT screening,
revisions may include: (1) A revised
roster structure; (2) various wording
edits to improve respondent
comprehension and flow; (3) the use of
revised materials, such as the lead letter,
study description and question &
answer brochure; (4) a conditional test
of a $5 screening incentive to assess
impact on response rates; and (5) the
inclusion of two outcome questions on
past month alcohol and past month
cigarette use at the end of the screening
to assess nonresponse bias from the
screening incentive.
For the NSDUH FT interview,
revisions may include: (1) A conditional
test of a $50 interview incentive to
assess impact on response rates; (2)
revisions to the DSM–5-based SUD
module as a result of prior testing in the
CVS; (3) the inclusion of new modules
on substance use treatment and mental
health service utilization; (4) the
addition of new and/or revised
questions on a variety of items such as
Electronic Nicotine Delivery Systems
(ENDS), synthetic drugs, pain and sleep,
vaping and needle use, and criminal
justice; (5) the addition of measures of
adolescent psychological distress and/or
impairment; (6) the expansion of suicide
items; and (7) other general
questionnaire revisions such as
clarifying wording and terminology,
reordering for improved question flow,
formatting changes, removal of
questions with low prevalence rates,
and other minor updates and revisions.
The total annual burden estimate for
the FT is shown below in Table 3.
TABLE 3—ANNUALIZED ESTIMATED BURDEN FOR REDESIGN FIELD TEST
Number of
respondents
Instrument
Total number
of responses
Hours per
response
Total burden
hours
Household Screening ...........................................................
Interview ...............................................................................
Screening Verification ..........................................................
Interview Verification ............................................................
8,110
4,000
246
600
1
1
1
1
8,110
4,000
246
600
0.083
1.000
0.067
0.067
673
4,000
17
40
Total ..............................................................................
8,110
........................
12,596
........................
4,730
Send comments to Janet Heekin,
SAMHSA Reports Clearance Officer,
Room 15E21B, 5600 Fishers Lane,
Rockville, MD 20857 or email a copy at
janet.heekin@samhsa.hhs.gov.
Written comments should be received
by August 12, 2019.
Dated: June 6, 2019.
Carlos Castillo,
Committee Management Officer.
Comments must reach the Coast
Guard on or before August 12, 2019.
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2019–0353]
Information Collection Request to
Office of Management and Budget;
OMB Control Number: 1625–0049
Coast Guard, DHS.
Sixty-day notice requesting
comments.
AGENCY:
ACTION:
In compliance with the
Paperwork Reduction Act of 1995, the
U.S. Coast Guard intends to submit an
Information Collection Request (ICR) to
the Office of Management and Budget
(OMB), Office of Information and
Regulatory Affairs (OIRA), requesting an
extension of its approval for the
SUMMARY:
17:00 Jun 11, 2019
You may submit comments
identified by Coast Guard docket
number [USCG–2019–0353] to the Coast
Guard using the Federal eRulemaking
Portal at https://www.regulations.gov.
See the ‘‘Public participation and
request for comments’’ portion of the
SUPPLEMENTARY INFORMATION section for
further instructions on submitting
comments.
A copy of the ICR is available through
the docket on the internet at https://
www.regulations.gov. Additionally,
copies are available from: Commandant
(CG–612), Attn: Paperwork Reduction
Act Manager, U.S. Coast Guard, 2703
Martin Luther King Jr. Ave. SE, Stop
7710, Washington, DC 20593–7710.
ADDRESSES:
BILLING CODE 4162–20–P
VerDate Sep<11>2014
following collection of information:
1625–0049, Waterfront Facilities
Handling Liquefied Natural Gas (LNG)
and Liquefied Hazardous Gas (LHG);
without change. Our ICR describe the
information we seek to collect from the
public. Before submitting this ICR to
OIRA, the Coast Guard is inviting
comments as described below.
DATES:
[FR Doc. 2019–12340 Filed 6–11–19; 8:45 am]
jbell on DSK3GLQ082PROD with NOTICES
Responses
per
respondent
Jkt 247001
Mr.
Anthony Smith, Office of Information
Management, telephone 202–475–3532,
or fax 202–372–8405, for questions on
these documents.
FOR FURTHER INFORMATION CONTACT:
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00111
Fmt 4703
Sfmt 4703
Public Participation and Request for
Comments
This notice relies on the authority of
the Paperwork Reduction Act of 1995;
44 U.S.C. Chapter 35, as amended. An
ICR is an application to OIRA seeking
the approval, extension, or renewal of a
Coast Guard collection of information
(Collection). The ICR contains
information describing the Collection’s
purpose, the Collection’s likely burden
on the affected public, an explanation of
the necessity of the Collection, and
other important information describing
the Collection. There is one ICR for each
Collection.
The Coast Guard invites comments on
whether this ICR should be granted
based on the Collection being necessary
for the proper performance of
Departmental functions. In particular,
the Coast Guard would appreciate
comments addressing: (1) The practical
utility of the Collection; (2) the accuracy
of the estimated burden of the
Collection; (3) ways to enhance the
quality, utility, and clarity of
information subject to the Collection;
and (4) ways to minimize the burden of
the Collection on respondents,
including the use of automated
collection techniques or other forms of
information technology. Consistent with
the requirements of Executive Order
13771, Reducing Regulation and
Controlling Regulatory Costs, and
E:\FR\FM\12JNN1.SGM
12JNN1
]]>Agencies
[Federal Register Volume 84, Number 113 (Wednesday, June 12, 2019)]
[Notices]
[Pages 27339-27341]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-12340]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Proposed Collection;
Comment Request
In compliance with section 3506(c)(2)(A) of the Paperwork Reduction
Act of 1995 concerning opportunity for public comment on proposed
collections of information, the Substance Abuse and Mental Health
Services Administration (SAMHSA) will publish periodic summaries of
proposed projects. To request more information on the proposed projects
or to obtain a copy of the information collection plans, call the
SAMHSA Reports Clearance Officer on (240) 276-1112.
Comments are invited on: (a) Whether the proposed collections of
information are necessary for the proper performance of the functions
of the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology.
Proposed Project: 2020 National Survey on Drug Use and Health Clinical
Validation Study and Redesign Field Test (OMB No. 0930-0110)--Revision
to 2019 NSDUH Collection
The National Survey on Drug Use and Health (NSDUH) is a survey of
the U.S. civilian, non-institutionalized population aged 12 years old
or older. The data are used to determine the prevalence of use of
tobacco products, alcohol, illicit substances, and illicit use of
prescription drugs. The results are used by SAMHSA, the Office of
National Drug Control Policy (ONDCP), federal government agencies, and
other organizations and researchers to establish policy, direct program
activities, and better allocate resources.
2020 NSDUH Main Study--
NSDUH must be updated periodically to reflect changing substance
use and mental health issues and to continue producing current data.
For the 2020 NSDUH main study the following changes from 2019 are
planned: (1) The addition of lifetime and recency questions about
vaping anything and vaping nicotine or tobacco; the addition of
lifetime and recency questions on synthetic marijuana and synthetic
stimulants; (2) the addition of questions in concordance with the
Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth
edition criteria (DSM-5) to measure the occurrence of marijuana
withdrawal symptoms, occurrence of prescription tranquilizer misuse
withdrawal symptoms and occurrence of craving for all substances; (3)
minor revisions to the marijuana marketplace module; and (4) other
minor wording changes to improve the flow of the interview, increase
respondent comprehension or to be consistent with text in other
questions.
By including these new questions in NSDUH, estimates may be
generated on the use of these substances among the general population
and allow SAMHSA to provide national-level estimates among adults and
adolescents on the use of vaping, synthetic marijuana, and synthetic
stimulants. In addition, because NSDUH collects demographic,
socioeconomic, and health information about each respondent, the
inclusion of these questions would permit a more detailed understanding
of factors associated with their use.
The new questions on craving for all substances and withdrawal for
marijuana/cannabis were added to the 2020 NSDUH main study to reflect
the updated DSM-5 diagnostic criteria for substance use disorders.
Questions
[[Page 27340]]
measuring withdrawal for tranquilizers have been added to ensure SUD
for tranquilizers is accurately assessed as well.
The marijuana marketplace module (originally dropped in the 2015
redesign questionnaire) was reinserted in the NSDUH main study
questionnaire starting in 2018 at the request of ONDCP but was
unchanged from the version previously used in the 2014 NSDUH. (This
module was not part of the NSDUH questionnaire from 2015-2017.) This
module consists of a series of questions that seek to gather data such
as the location, quantity, cost and type of marijuana being purchased
across the nation. Revisions have been made to this module for 2020 to
reflect the availability that marijuana can now be purchased from a
retail store or dispensary.
As with all NSDUH/NHSDA surveys conducted since 1999, the sample
size of the NSDUH main study for 2020 will be sufficient to permit
prevalence estimates for each of the fifty states and the District of
Columbia. (Prior to 2002, the NSDUH was referred to as the National
Household Survey on Drug Abuse (NHSDA).) The total annual burden
estimate for the NSDUH main study is shown below in Table 1.
Table 1--Annualized Estimated Burden for 2020 NSDUH
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Hours per Total burden
Instrument respondents respondent of responses response hours
----------------------------------------------------------------------------------------------------------------
Household Screening............. 143,255 1 143,255 0.083 11,890
Interview....................... 69,007 1 69,007 1.000 69,007
Screening Verification.......... 4,348 1 4,348 0.067 291
Interview Verification.......... 10,351 1 10,351 0.067 694
-------------------------------------------------------------------------------
Total....................... 143,255 .............. 226,961 .............. 81,882
----------------------------------------------------------------------------------------------------------------
Clinical Validation Study--
In addition, a Clinical Validation Study (CVS) is planned to be
embedded within the first six months of 2020 NSDUH main study data
collection to assess revisions to the substance use disorders (SUD)
module to be consistent with the DSM-5. The CVS will examine the
validity of this revised NSDUH assessment of SUD by administering
questions to adults and adolescents who will then be interviewed by
clinical interviewers (who are blinded to the NSDUH main study
responses) and classified as having or not having substance use
disorders based on past year DSM-5 disorders, as assessed by the
Structured Clinical Interview for DSM-5 (SCID-5).
During CVS data collection from January through June 2020,
approximately 1,500 NSDUH main study interview respondents will be
selected for a follow-up clinical interview at the end of the main
study interview in order to produce a final sample size of
approximately 825 CVS respondents. These follow-up clinical interviews
will be conducted via telephone using the SCID-5 within two to four
weeks following the NSDUH main study interview.
Many of the procedures and protocols planned for inclusion in this
CVS are based upon those previously employed as part of the 2018
National Mental Health Study (approved under OMB No. 0930-0380) and the
2008-2012 NSDUH Mental Health Surveillance Study (approved as an add-on
to NSDUH under OMB No. 0930-0110).
Also, to complete training prior to CVS data collection, each
clinical interviewer candidate hired must successfully administer the
follow-up clinical interview with a volunteer respondent. These 70
certification interviews will be administered in the same manner as CVS
follow-up clinical interviews.
The total annual burden estimate for the CVS is shown below in
Table 2.
Table 2--Annualized Estimated Burden for 2020 NSDUH CVS
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Hours per Total burden
Instrument respondents respondent of responses response hours
----------------------------------------------------------------------------------------------------------------
Follow-Up Clinical Interviews... 826 1 826 0.83 686
Follow-Up Clinical 70 1 70 0.83 58
Certifications.................
-------------------------------------------------------------------------------
Total....................... 896 .............. 896 .............. 744
----------------------------------------------------------------------------------------------------------------
Redesign Field Test--
Also, as part of SAMHSA's ongoing effort to ensure NSDUH continues
producing current and accurate data, a Redesign Field Test (FT) is
planned from August through November 2020 to assess potential revisions
to the NSDUH main study questionnaire. These revisions are designed to
address changing policy and research data needs; in addition,
modifications to associated survey materials and methods are designed
to improve the quality of estimates and the efficiency of data
collection. Planned FT modifications include changes to respondent
incentives, respondent materials, the household screening
questionnaire, the interview questionnaire, and other data collection
methods.
The FT is essential for providing a thorough examination of these
planned changes prior to their deployment on the NSDUH main study to
determine potential impact across operational and substantive domains,
including effects on data quality (as measured by outcomes such as unit
nonresponse, item nonresponse, and survey responses), questionnaire
timing, data collection efficiency, and possible differences in
reporting of substance use or mental health items.
During FT data collection from August through November 2020,
conducted separately from ongoing 2020 NSDUH main study data collection
at that time, screenings will be completed
[[Page 27341]]
with approximately 8,110 English-speaking respondents in the contiguous
United States. (Alaska and Hawaii are excluded from the FT to control
study costs.) From those screenings, approximately 4,000 respondents,
as representatives of the civilian, noninstitutional population aged 12
years old or older, are expected to complete a FT interview using the
revised questionnaire and materials.
For the NSDUH FT screening, revisions may include: (1) A revised
roster structure; (2) various wording edits to improve respondent
comprehension and flow; (3) the use of revised materials, such as the
lead letter, study description and question & answer brochure; (4) a
conditional test of a $5 screening incentive to assess impact on
response rates; and (5) the inclusion of two outcome questions on past
month alcohol and past month cigarette use at the end of the screening
to assess nonresponse bias from the screening incentive.
For the NSDUH FT interview, revisions may include: (1) A
conditional test of a $50 interview incentive to assess impact on
response rates; (2) revisions to the DSM-5-based SUD module as a result
of prior testing in the CVS; (3) the inclusion of new modules on
substance use treatment and mental health service utilization; (4) the
addition of new and/or revised questions on a variety of items such as
Electronic Nicotine Delivery Systems (ENDS), synthetic drugs, pain and
sleep, vaping and needle use, and criminal justice; (5) the addition of
measures of adolescent psychological distress and/or impairment; (6)
the expansion of suicide items; and (7) other general questionnaire
revisions such as clarifying wording and terminology, reordering for
improved question flow, formatting changes, removal of questions with
low prevalence rates, and other minor updates and revisions.
The total annual burden estimate for the FT is shown below in Table
3.
Table 3--Annualized Estimated Burden for Redesign Field Test
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Hours per Total burden
Instrument respondents respondent of responses response hours
----------------------------------------------------------------------------------------------------------------
Household Screening............. 8,110 1 8,110 0.083 673
Interview....................... 4,000 1 4,000 1.000 4,000
Screening Verification.......... 246 1 246 0.067 17
Interview Verification.......... 600 1 600 0.067 40
-------------------------------------------------------------------------------
Total....................... 8,110 .............. 12,596 .............. 4,730
----------------------------------------------------------------------------------------------------------------
Send comments to Janet Heekin, SAMHSA Reports Clearance Officer,
Room 15E21B, 5600 Fishers Lane, Rockville, MD 20857 or email a copy at
[email protected].
Written comments should be received by August 12, 2019.
Dated: June 6, 2019.
Carlos Castillo,
Committee Management Officer.
[FR Doc. 2019-12340 Filed 6-11-19; 8:45 am]
BILLING CODE 4162-20-P
